Ariad Shares Continue to Surge Amidst Buyout Rumors

Shares of Ariad Pharmaceuticals (NASDAQ: ARIA ) continue to surge following commercial availability of Iclusig and the UK Daily Mail's report on a potential buyout. On January 17, Ariad reported on the commercial availability of Iclusig^® (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute